←Back to Expert Scholars
Translational Medicine / 转化医学KRAS G12C Later-Line Therapy
Pasi Janne
MD, PhD
🏢Dana-Farber Cancer Institute🌐USA
Professor of Medicine
112
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Pasi Janne has led combination trials of KRAS G12C inhibitors with SHP2 and SOS1 inhibitors for later-line NSCLC. His clinical program addresses strategies to overcome adaptive resistance to KRAS-targeted monotherapy. He brings extensive experience from EGFR-targeted therapy resistance to the KRAS combination therapy field.
Share:
🧪Research Fields 研究领域
KRAS G12C combinations
SHP2 inhibitors
Targeted therapy
NSCLC treatment
Combination strategies
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Pasi Janne 的研究动态
Follow Pasi Janne's research updates
留下邮箱，当我们发布与 Pasi Janne（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment